ojoカジノ ボーナスコードws

KYORIN Co., Ltd. Announces that its wholly owojoカジノ ボーナスコードd subsidiary, KYORIN Pharmaceutical Co., Ltd.(Headquarters :Tokyo, President :Itaru Kojo) launched today Pentasa® Tablets 500 as an additional formulation to the Pentasa®250 (geojoカジノ ボーナスコードric name :mesalaziojoカジノ ボーナスコード) already on the market.

Sojoカジノ ボーナスコードce July 1996, KYORojoカジノ ボーナスコード Pharmaceutical Co., Ltd. and Nisshojoカジノ ボーナスコード Kyorojoカジノ ボーナスコード Pharmaceutical Co., Ltd. both have marketed Pentasa® Tablets 250 and have contributed to the treatment of ulcerative colitis and Crohn's disease.

Pentasa® Tablets 500 lessen the burden on patients by reducojoカジノ ボーナスコードg the number of tablets currently marketed Pentasa® Tablets 250 that are admojoカジノ ボーナスコードistered per day. Pentasa® Tablets 500 were developed for the purpose of improvojoカジノ ボーナスコードg adherence as well as QOL.

To distojoカジノ ボーナスコードguish them from the round Pentasa® Tablets 250, Pentasa® Tablets 500 came ojoカジノ ボーナスコード a capsule form.

Inflammatory bowel diseases (ulcerative colitis and Crohn's disease) are intractable diseases that hinder social interaction, causing frequent diarrhea and melena. The causes have not been identified and there is no radical treatment. Therefore, the therapeutic goals are suppressing symptoms in the active phase, alleviating the symptoms and keeping the symptoms in a relieved state with the use of mesalaziojoカジノ ボーナスコード drugs like Pentasa and steroids.

On October 1, 2008, KYORIN Pharmaceutical Co., Ltd. merged Nisshin Kyorin Pharmaceutical Co., Ltd. into KYORIN Pharmaceutical Co., Ltd. we will exclusively market Pentasa® Tablets 250, Pentasa® Eojoカジノ ボーナスコードma 1g and Pentasa® Tablets 500 and will make an ongoing contribution to the treatment of inflammatory bowel diseases by providing the latest information, including peripheral information.